FDA Drug Recalls

Recalls / Class II

Class IID-1125-2019

Product

Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.

Brand name
Testosterone Cypionate
Generic name
Testosterone Cypionate
Active ingredient
Testosterone Cypionate
Route
Intramuscular
NDCs
69097-536, 69097-537
FDA application
ANDA210362
Affected lot / code info
Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.

Why it was recalled

Presence of Particulate Matter.

Recalling firm

Firm
InvaGen Pharmaceuticals, Inc.
Manufacturer
Cipla USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
550 S Research Pl, N/A, Central Islip, New York 11722-4415

Distribution

Quantity
75968 vials
Distribution pattern
Nationwide in the U.S.A.

Timeline

Recall initiated
2019-03-22
FDA classified
2019-04-15
Posted by FDA
2019-04-24
Terminated
2022-08-16
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1125-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Testosterone Cypionate · FDA Drug Recalls